The company trades various industrial glass products and mirrors while providing technical consultancy and advisory services to the glass industry.
The company operates in a highly fragmented trading business with no evidence of cost advantages or brand power, as reflected by chronically negative average ROCE and ROE. The reliance on related-party entities for supply and sales suggests the business lacks an independent competitive standing.
Capital has been deployed into a low-margin trading business that has failed to generate positive returns on equity over the long term. Recent actions include increasing debt to fund working capital and shifting the registered office, but there is no evidence of value-creating reinvestment.
The company's collapse was driven by its inability to service a heavy debt load with a business model that fundamentally destroys capital. As interest rates remained sticky, the razor-thin interest coverage evaporated, and the lack of a permanent CFO led to a total breakdown in financial controls. The reliance on related-party transactions eventually turned from a crutch into a liability when those entities could no longer subsidize the trading losses, leaving the company with no independent path to profitability and a balance sheet burdened by unserviceable liabilities.
RichFakir rates Agarwal Fortune India Ltd's business quality as poor — 11/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Agarwal Fortune India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Agarwal Fortune India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Agarwal Fortune India Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →